Alzheimer’s disease


DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE

NICE Appraisals

TA217 Donepezil, galantamine rivastigmine and memantine for the treatment of Alzheimer’s disease (March 2011)

TA111  Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease (including a review of TA19) (March 2010)

DSU Report

A review of the Eisai / Pfizer economic model on the cost-effectiveness of donepezil (June 2010) a report contributing to the PenTAG report “The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatement of Alzheimer’s disease (review of TA111): a systematic review and economic model

Donepezil, rivatigmine, galantamine and memantine for the treatment of Alzheimer’s disease: A review of comments submitted by consultees on the reliability of economic model (March 2009) for TA111